Penn Medicine and IBA (Ion Beam Applications) announced on September 28, 2026 the formation of Noventra Oncology Alliance, a new joint venture designed to help healthcare providers develop, implement, and optimize proton therapy and advanced radiation oncology programs. The company will provide an integrated service offering spanning strategic and financial planning, clinical readiness, program implementation, and long-term operational performance.
“By combining Penn Medicine’s decades of experience building and operating one of the world’s leading proton therapy programs with IBA’s expertise in proton therapy technology and implementation, we are creating a unique platform to help healthcare organizations deliver exceptional care to patients while building sustainable, high-performing oncology programs,” said James Metz, MD, chair of Radiation Oncology at the University of Pennsylvania Perelman School of Medicine.
More Than Equipment
As proton therapy becomes an increasingly important part of comprehensive cancer care, health systems around the world are working to expand access while ensuring clinical excellence and financial sustainability. But building a successful proton therapy program requires more than buying equipment. Organizations must manage strategic planning, capital investment, reimbursement, workforce development, clinical readiness, operational performance, research infrastructure, and long-term program growth.
Noventra brings together Penn Medicine’s clinical, operational, research, and education expertise with IBA’s global leadership in proton therapy technology, project development, and implementation. Unlike traditional advisory models, the joint venture combines a world-leading clinical operator with the global leader in proton therapy technology, creating a single partner that can support organizations from initial strategy through long-term operational excellence.
“A center that is unable to treat patients at scale or operate sustainably ultimately falls short of its purpose,” said Henri de Romrée, Deputy CEO of IBA. “By bringing together IBA’s global expertise in proton therapy technology and project implementation with Penn Medicine’s clinical and operational leadership, Noventra Oncology Alliance helps organizations reduce the clinical, operational, and financial risks associated with developing advanced radiation oncology programs. It will also be key to reinforcing the value of this technology in cancer treatment and accelerating its broader adoption.”
Noventra’s services will be showcased at the ASTRO Annual Meeting 2026 in Boston, at IBA’s booth (#843) and Penn Medicine’s booth (#1722).
About Penn Medicine
Penn Medicine is one of the world’s leading academic medical centers, dedicated to medical education, biomedical research, patient care, and community service. It consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school. Penn Medicine teams have pioneered innovations including CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology and the leading supplier of equipment and services in proton therapy, as well as industrial sterilization, radiopharmaceuticals, and dosimetry. Based in Louvain-la-Neuve, Belgium, IBA employs approximately 2,300 people worldwide, is a certified B Corporation, and is listed on Euronext (IBAB.BR).
